Translational science, built into a company.
Miragen Private Limited was founded to close the distance between a well-published research program in nanomedicine and the clinics that need it — one granted patent and one validated platform at a time.
To revolutionize oncology care by bridging the gap between advanced nanotechnology research and clinical application, enabling early detection and precision therapy.
Label-Free Optical Diagnostics
Rapid, portable biosensors for biomarkers in a liquid biopsy.
Brain-Targeted Nanotherapeutics
Non-invasive intranasal delivery that bypasses the blood-brain barrier.
Localized Relapse Control
Injectable, self-gelling wafers for post-surgical therapy.
Transmucosal & Dermal Platforms
Lipid nanoparticles and microneedles for enhanced delivery.
Academic excellence behind the science
Dr. Puja Sandbhor
Director & Lead Scientist
Postdoctoral Fellow in Neuro-Oncology at Johns Hopkins University School of Medicine, MD, USA, following a Ph.D. and postdoctoral fellowship at the Indian Institute of Technology Bombay (IIT Bombay). Her work is specialized in blood-brain barrier biology, nanomedicine formulation, and translational cancer therapeutics — the scientific foundation for every Miragen platform.
- IN 408307 — Injectable Wafer System
- IN 366070 — Lipid-Based Dermal Delivery
- 10+ peer-reviewed papers
- Including Nanoscale, J Control Release
10+ Years R&D
A decade of focused work in nanomedicine and BBB-targeted drug delivery.
Translational Research
Bridging the bench-to-bedside gap with application-driven formulation science.
IP Generation
Two patented, novel delivery systems with a defined pipeline behind them.
Global Collaboration
Research grounded in institutions including IIT Bombay and Johns Hopkins University.
Scientific publications & validation
Every Miragen platform traces back to published, peer-reviewed research across neuro-oncology, BBB crossing, biosensors, and drug delivery.
Spatial specific delivery of combinational chemotherapeutics for glioblastoma heterogeneity
Journal of Controlled Release; 348:1004–1015
Validates efficacy against intratumoral heterogeneity in GBM using dual-drug loaded nanoparticles.
Nanomedicine as a multimodal therapeutic paradigm
Nanoscale; 16(13):6330–6364
Establishes the framework for next-generation precision therapy using functionalized nanocarriers.
Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth
Drug Delivery and Translational Research
Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology
Frontiers in Oncology; 13:1168454
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for post-surgical GBM therapy
Nanoscale; 14(35):12773–12788
Non-invasive transferrin-targeted nanovesicles sensitize resistant glioblastoma multiforme tumors
Nanoscale; 14(1):108–126
Immune response recalibration using immunotherapy and biomimetic nano-therapy against high-grade gliomas
Sandbhor, P. et al. — Asian Journal of Pharmaceutical Sciences